Immune Thrombocytopenia (ITP) Market 2025: Opportunity Analysis and Forecasts

"The Latest Research Report OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

About Immune Thrombocytopenia Market

Immune Thrombocytopenia (ITP) is an auto-immune-related bleeding disorder characterized by a low platelet count. Patients with severe ITP often experience fatigue, bruising, and reduced quality of life. Although most ITP cases are not fatal, approximately 3% of chronic refractory ITP patients die of complications, such as intracranial hemorrhage and infection. Most of the ITP treatments available are off-label drugs. In 2008, a class of new drug, the thrombopoietin receptor agonists (TRAs), was approved and revolutionized the treatment of ITP.

GlobalData estimates the 2015 sales for ITP at approximately $928m across the 7MM covered in this report. The market is expected to grow modestly to $985m in 2025, at a CAGR of 0.6%. This growth will be mainly driven by the increasing uptake of TRAs, Amgen/Kirins Nplate/Romiplate (romiplostim) and Novartis Promacta/Revolade (eltrombopag). However, GlobalData expects, starting in 2022, Nplate and Promacta will face patent expiry and subsequent biosimilar/generic erosion; this represents the strongest barrier of ITP market growth.

Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/1135703

The ITP pipeline activity is weak, with only one active late-stage pipeline agent, Rigel Pharmaceuticals fostamatinib; however, GlobalData expects this drug to struggle for uptake because of the modest efficacy shown in its pivotal trials. Overall, the treatment landscape of ITP is not anticipated to substantially change throughout the forecast period of 2015-2025.

Key Questions Answered

- What are the key drivers behind the increasing uptake and market penetration of the TRA-class molecules, since their approval in 2008, and what is the trend of TRA use in the forecast period?
- When will the key patent of Nplate and Promacta expire, and how will it affect drug sales and the overall ITP market in the 7MM?
- What are the struggles for pipeline drug development in the ITP market? Why does GlobalData expect the pipeline drugs to introduce minimal impacts on the marketspace during the forecast period?

Scope

- Overview of ITP, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized ITP therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (including pediatric, adult primary, and adult secondary), forecast from 2015 to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ITP therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for ITP therapy. The most promising candidate in Phase III development is profiled.
- Analysis of the current and future market competition in the global ITP therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

View Report @ https://www.marketresearchreports.biz/reports/1135703/opportunityanalyzer-immune-thrombocytopenia-itp-opportunity-analysis-and-forecasts-to-2025-market-research-reports

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global ITP therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ITP therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/1135703

Table of Contents

1 Table of Contents 8
1.1 List of Tables 13
1.2 List of Figures 16
2 Introduction 18
2.1 Catalyst 18
2.2 Related Reports 18
2.3 Upcoming Related Reports 19
3 Disease Overview 20
3.1 Etiology and Pathophysiology 20
3.1.1 Etiology 20
3.1.2 Pathophysiology 22
3.2 Phases and Severity of ITP 24
3.3 Symptoms 25
3.4 Prognosis 26
3.5 Quality of Life 27
4 Epidemiology 29
4.1 Disease Background 29
4.2 Risk Factors and Comorbidities 29
4.3 Global Trends 31
4.3.1 US 33
4.3.2 5EU 34
4.3.3 Japan 35
4.4 Forecast Methodology 35
4.4.1 Sources Used Tables 36
4.4.2 Forecast Assumptions and Methods 39
4.4.3 Sources Not Used 47
4.5 Epidemiological Forecast for ITP (2015-2025) 48
4.5.1 Diagnosed Prevalent Cases of ITP 48
4.5.2 Age-Specific Diagnosed Prevalent Cases of ITP 52
4.5.3 Sex-Specific Diagnosed Prevalent Cases of ITP 56
4.5.4 Age-Standardized Diagnosed Prevalence of ITP 60
4.5.5 Diagnosed Incident Cases of ITP 63
4.5.6 Age-Specific Diagnosed Incident Cases of ITP 67
4.5.7 Sex-Specific Diagnosed Incident Cases of ITP 71
4.5.8 Age-Standardized Diagnosed Incidence of ITP 75
4.6 Discussion 77
4.6.1 Epidemiological Forecast Insight 77
4.6.2 Limitations of the Analysis 79
4.6.3 Strengths of the Analysis 80
5 Current Treatment Options 81
5.1 Overview 81
5.2 Diagnosis and Treatment 81
5.2.1 Diagnosis 82
5.2.2 Treatment Guidelines and Leading Prescribed Drugs 85
5.3 Clinical Practice 86
5.3.1 Decision on the Initiation of Treatment 86
5.3.2 First-Line Treatment 89
5.3.3 Second-Line Therapy 96
5.4 Product Profiles - Thrombopoietin Receptor Agonists 108
5.4.1 Nplate (Romiplostim) 108
5.4.2 Promacta/Revolade (Eltrombopag) 123
6 Unmet Needs Assessment and Opportunity Analysis 139
6.1 Overview 139
6.2 Safer and More Efficacious First-Line Therapy 139
6.2.1 Unmet Need 139
6.2.2 Gap Analysis 140
6.2.3 Opportunity 141
6.3 High Treatment Cost of Thrombopoietin Receptor Agonists 141
6.3.1 Unmet Need 141
6.3.2 Gap Analysis 142
6.3.3 Opportunity 143
6.4 Second-Line Therapeutic Options that Offer Long-Term Remission 143
6.4.1 Unmet Need 143
6.4.2 Gap Analysis 144
6.4.3 Opportunity 145
6.5 New Treatment for Multiple Drug Refractory Patients 146
6.5.1 Unmet Need 146
6.5.2 Gap Analysis 146
6.5.3 Opportunity 147
6.6 Difficulties in Clinical Trial Patient Recruitment 147
6.6.1 Unmet Need 147
6.6.2 Gap Analysis 148
6.6.3 Opportunity 149

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.